|
We're finally at the starting gate in learning about the brain.
Serious discoveries will be forthcoming in genomics, developmental
behaviors, disease inhibition, and the brain's interaction with the
body. The brain is the last frontier in medicine, uncharted
territory that commands the attention of any true explorer. To
read more about health-related topics on the Global Province, also see Stitch in Time.
262. -new-
Good Things Come to Those Who Wait
“Good Things Come to Those Who Wait,” and we’re not talking about Heinz ketchup. We’re not even sure that patience is a virtue, but Walter Mischel at Stamford believes that kids who have a propensity for delaying gratification tend to make out better in life. Once Mischel began analzying the results, he noticed that low delayers, the children who rang the bell quickly, seemed more likely to have behavioral problems, both in school and at home.” “Don’!” New Yorker, May 18, 2009, pp. 26-32. Ozlem Ayduk at Berkeley “found that low-delaying adults have a significantly higher body-mass index and are more likely to have had problems with drugs...” Those with high delay abilities have learned to trick themselves out of speedily pursuing a desired object, using all sort of tactics to forget, for instance, a marshmellow or something else they lust after. “In adults, this skill (avoiding thinking about a desire) is often referred to as metacognition, or thinking about thinking, and it’s what allows people to outsmart their shortcomings.” Mischel hopes to look at a number of mental perturbations—such as OCD and attention deficit disorder—to see if they can be helped through attention control. (06-24-09)
261. Alzheimer’s
Vaccine: Making Haste Slowly
Back on January 18,
2001, the Harvard
Gazette reported
that
“Alzheimer’s Vaccine Looks Promising: Brain Deterioration Slowed by
Nose
Drops.” At that time Harvard had tried
the drops on mice, and sundry vaccine trials of a minor sort had been
used at
many other locations. As it
happens, the vaccine did not progress very fast, as indicated in a Gazette article of October 20, 2005. “A
vaccine has
been developed against the proteins that cause the amyloid plaques,
Selkoe
said. Though it failed in trials, partial results obtained indicated
that after
just two injections patients' brains were partly cleared of the
plaques.” Much of the delay has been
blamed on
lack of Government funding, and drug company aversion to the sundry
risks
involved in vaccine development.
The researchers do not mention that their fundamental
assumptions may be
wrong. (05-20-09)
260.
All About Obsession
Obsession:
A History goes back a few centuries to trace the movement of
‘obsession’ away from a malady just perceived as an oddity to a
two-side phenomena where it is simultaneously thought of as an illness
and as the goad the produces many discoveries, scientific and
otherwise. Economist, November 1, 2008, p. 96. In a
couple of decades, obsessive-compulsive behavior has gone from a rare
ailment—one in 2000 in 1973 to 2 or 3 people in 100. As we have
said elsewhere,
our understanding of the obsessive compulsive mechanism is not very
advanced, nor have we done as much work as we could on harnessing the
creativity and focus of obsessives for the benefit of society.
(04-01-09)
259. Rewiring Autistic Children
Amy O’Dell, who has an autistic child, has a school where a pot pourri
of techniques are used to get autistic kids to forge new connections in
their heads. Forbes, May 5, 2008, pp.54-58.
“This is Jacob’s Ladder,
the school O’Dell founded in 1999 to treat children with neurological
disorders.” Most have severe autism. Her work stems from the
theory that the brain is plastic and can be reworked to form new
connections. There are no clinical studies substantiating this,
but others have had successes with Alzheimer’s patients and autistics
using computer games and other such stimulants. (03-04-09)
258. Bad Memory: Sweet Amnesia
Those who are readers of Proust will remember that he had an awfully
keen memory. Those who have lovingly followed his voluminous writing on
recapturing the past marvel at the completeness with which he recalled
the madeleine of youth
such that it kindled all his senses. Ironically, now, we are learning
that sugar then and sugar now actually clogs our memories and makes it
harder and harder to recall anything. The negative power of glucose,
particularly as we age, is tackled in “Blood Sugar Control Linked to
Memory Decline,” New York Times, December 31, 2008.
“The study, by researchers at Columbia University
Medical Center and funded in part by the National Institute on
Aging, was published in the December issue of Annals
of Neurology.” “The ability to regulate glucose starts
deteriorating by the third or fourth decade of life….Since glucose
regulation is improved with physical
activity, Dr. Small said, ‘We have a behavioral
recommendation—physical exercise.’” “They found a correlation
between elevated blood glucose levels and reduced cerebral blood
volume, or blood flow, in the dentate gyrus, an indication of reduced
metabolic activity and function in that region of the brain.” (02-04-09)
257.The
Infinite Mind
The
Infinite Mind is an absolutely foolish name for a radio series,
just the sort of thing euphemistic types in public broadcasting like to
drum up. Big oceanic names to label small puddles. But it
works, and we occasionally take a look at its offerings. “The
Infinite Mind program peeping-toms into the inner workings of the human
mind through interviews with various medical professionals, artists,
and those coping with mental illness. Guests of the program have
included everyone from comedienne Margaret Cho to left-handed boxers,
or ‘southpaws,’ as they are known in the business. Recent
programs have included shows on the nature of altruism, shoplifting,
Tourette's syndrome, and internal body clocks,” according to the Scout Report.
(9/10/08)
256. Finding Your Bliss
It’s an inspiration and one-half to read about Jill Bolte Taylor,
formerly a neuroscientist at Harvard and now creatively semi-retired in
Bloomington, Indiana, not far from the university. On December
10, 1996, at age 37, she had a stroke which more or less shut down her
left temporal lobe—and all sorts of functionality—but nonetheless left
her feeling great, as if she had discovered Nirvana (See the New
York Times, May 25, 2008, pp. ST1& 7. Lost, for the
moment, was her ability to speak, the capacity to decipher letters and
numbers, even the connections to recognize her mother who,
incidentally, nursed her back to health. All this she has
recounted in her memoir, My
Stroke of Insight. Surgery and eight years of recovery were
required for her to bring back her whole brain. “Her message,
that people can choose to live a more peaceful, spiritual life by
sidestepping their left brain, has resonated widely.” She has
talked about her experience at the TED
Conference and her thoughts can also be found on Oprah Winfrey’s
website. The kids in the 1960s were only prophetic when they talked
about following their bliss. (7/16/08)
255. American Psychiatry Up To 1900
The National Institutes of Health provides an online
history of medicine, “Diseases
of the Mind” forming one part. It is more of a chronicle,
than a history, sketchy at best. After we admit that this is
lightweight, we can still salute a couple of facets. It provides
a short list of seminal 19th-century figures in psychiatry—as well as
some flavor of the debates that stalked this field in that
period. To be more complete, we would have to see something on
America’s unique contribution to the discipline. (7/2/08)
254. Brain Pattern Behind OCD
“Cambridge researchers have discovered that individuals
with obsessive compulsive disorder (OCD) and their close family members
have distinctive patterns in their brain structure. This is the
first time that scientists have associated an anatomical trait with
familial risk for the disorder.” “Lara Menzies, in the Brain
Mapping Unit at the University of Cambridge, explains, ‘Impaired brain
function in the areas of the brain associated with stopping motor
responses may contribute to the compulsive and repetitive behaviours
that are characteristic of OCD. These brain changes appear to run
in families and may represent a genetic risk factor for developing the
condition. The current diagnosis of OCD available to
psychiatrists is subjective and therefore knowledge of the underlying
causes may lead to better diagnosis and ultimately improved clinical
treatments.’” (University of Cambridge Press Release, 16 November
2007). Also see “Neurocognitive
endophenotypes of obsessive-compulsive disorder,” Brain,
December 2007. (6/18/08)
253. Molecule to Inhibit Alzheimer’s
Arun Ghosh, a Purdue professor, designed the molecule
that could allow for intervention in Alzheimer’s early
stages. “The molecule, called a beta-secretase inhibitor,
prevents the first step in a chain of events that leads to amyloid
plaque formation in the brain. This plaque formation creates
fibrous clumps of toxic proteins that are believed to cause the
devastating symptoms of Alzheimer’s.” Stage one work showed a
single dose of the drug produced a greater than 60 percent reduction of
plasma amyloid beta. “CoMentis
plans to begin a phase II clinical study of the drug, oral CTS-21166,
in Alzheimer's patients in 2008.” (Purdue
News Release, January 17, 2008.) We caution readers that
plaque seems to be more of a symptom than a part of the disease
mechanism, so it remains to be seen if its reduction positively affects
the disease itself. We suggest a look at Ghosh publications.
(5/14/08)
252. Brain Oxygen Monitor
“A new noninvasive diagnostic technology could give
doctors the single most important sign of brain health: oxygen
saturation. Made by an Israeli company called OrNim and slated for trials on
patients in U.S. hospitals later this year, the technology, called
targeted oximetry, could do what standard pulse oximeters can’t.”
“OrNim’s new device uses a technique called ultrasonic light tagging to
isolate and monitor an area of tissue the size of a sugar cube located
between 1 and 2.5 centimeters under the skin. The probe, which
rests on the scalp, contains three laser light sources of different
wavelengths, a light detector, and an ultrasonic emitter.” See
the MIT Technology Review, January 29, 2008. (5/14/08)
251. Rip Van Winkles
We’re inclined to think many brain-afflicted patients
are beyond the pale, without consciousness, not sentient, since they
are without utterance, and seemingly immune to stimulus. Brain
scans are revealing, however, that so-called vegetative people are
often more brain-active than we believe, as reported by Jerome Groopman
in “Silent Minds,” New Yorker, October 15, 2007,
pp.38-43. A British neuroscientist, Adrian Owen, at the
University of Cambridge has scanned several dozen people since 1997,
sometimes detecting signs of recognition to auditory stimuli. The
prognosis, however, with patients suffering from oxygen deprivation is
much worse than that of those afflicted by head injuries. (4/30/08)
250. The Age of Indecision
An awesome amount of research painfully proves the
obvious. The elderly, says a recent body of work, have a hard
time making decisions and are prone to poor judgments. Natalie
Denberg at the University of Iowa led the research team. For more
on this, read “Brain
Deficits In Older Adults Affect Decisions, Increase Vulnerability”
from TS-Si News Service, 15 January 2008. Also see, “The
orbitofrontal cortex, real-world decision making, and normal
aging.” Denburg NL, Cole CA, Hernandez M, Yamada TH, Tranel D,
Bechara A, Wallace RB. Ann. N.Y. Acad. Sci. 1121: 480–498 (2007). doi:
10.1196/annals.1401.031. The interesting question, of course, is
what keeps seniors in good running condition, and what kinds of things
inhibit such deterioration. Clearly the brain has to be used to
keep in tune. (4/16/08)
249. Shrink Show
TV shows about the brain and psychiatry continue to edge
into TV niche markets. The latest is “In Treatment,”
which is to be shown 9:30-10:00 PM on HBO, five nights a week.
“The drama, about a highly principled successful psychotherapist … and
five of his patients—not to mention the therapist’s own therapist” is
to run for nine weeks. See “Secrets and Lies,” Wall Street
Journal, January 25, 2008, p. W6. The Journal
reviewer is fascinated by the series, but the San
Francisco Chronicle considers it a snooze, probably
telling us a great deal about both newspapers, both cities, and both
reviewers. (4/2/08)
248. Garlic and Brain Cancer?
“Numerous studies provide evidence that garlic and its
organo-sulfur compounds are effective inhibitors of the cancer process,
most notably for prostate and stomach cancers. For the first time,
those compounds have been identified as effective against glioblastoma,
a type of brain tumor equivalent to a death sentence within a short
period after diagnosis.” “Cancer cells are known to have an incredibly
high metabolism, as they require much energy to divide cells for rapid
growth. In this study, it has been shown that garlic compounds produce
reactive oxygen species in rapidly growing brain cancer cells,
essentially gorging them to death with activation of multiple death
cascades.” “As for those who seek to take advantage of any
potential anti-cancer benefits from garlic now, certain rules
apply. Ray said people should cut and peel a piece of fresh
garlic and let it sit for fifteen minutes before eating or cooking it.
This amount of time is needed to release an enzyme (allinase) that
produces these anti-cancer compounds. Both Ray and Banik caution
the public in eating too much garlic, noting that too much of it can
cause diarrhea, allergies, internal bleeding, and bad breath and body
odor, among other problems, so it is important to monitor garlic
consumption.” As usual, we are a long ways away from an effective
botanical, and the claims for garlic always get a little
overblown. See Press Release, Medical University of South
Carolina, 27 August 2007. (3/12/08)
247.
-new- HerdSell
“Now researchers are investigating how ‘swarm intelligence’ (that is,
how ants, bees, or any social animal, including humans, behave in a
crowd) can be used to influence what people buy” (The Economist,
November 12, 2006, p. 90). Please understand that The Economist
folks got it exactly backwards here. With ‘swarm intelligence” the
crowd is immensely smarter than any of the individuals who, on their
own, may be dumb or worse. What the writer means to speak about
here is “lemming behavior” where all the creatures in a crowd march
over a cliff, nudged on by the leaders of the pack.
Zeeshan-ul-hassan Usmani, a computer scientist at Princeton, and
Ronaldo Menezes of the Florida Institute of Technology have tried to
capitalize on the tendency of consumers to buy what is perceived as
popular. What they do, with scanners, is show each individual
consumer how many of his co-shoppers in the store at the moment have
bought the product he is looking at. Fact is, this idea is still
in test, although both Wal-Mart and Tesco were slated to give it a
whirl. Matthew Salganik, formerly of Columbia University and now
at Princeton, has shown that consumers may be inclined to buy or
download songs that have been shown to be quite popular. RanKing
RanQueen, a convenience chain in Japan, only sells very popular
goods, and the rankings are updated weekly. “Icosystems … in
Cambridge, Massachusetts” aims to use social networking to bolster
sales. In general, the key is to get the ranking or popularity of
a good communicated to enough people. Menezes has
published widely on ‘swarm intelligence.’ See the PBS
program on RanKing RanQueen. (3/12/08)
246. Brain Institute a Good Idea? Maybe
“David
Fitzpatrick, a professor of neurobiology at Duke University, has
been named the first director of the new interdisciplinary Institute
for Brain, Mind, Genes, and Behavior.” “Duke’s research into
brain function is now spread across a number of units on campus,
including the Department of Psychology and Neuroscience, the Department
of Neurobiology, the Department of Psychiatry and Behavioral Sciences,
the Center For Cognitive Neuroscience, the Department of Pharmacology,
the Biomedical Engineering Department, the Center For Brain Imaging And
Analysis, the Conte Center For The Neuroscience Of Depression, the
Preston Robert Tisch Brain Tumor Center, the Center For Neuroeconomic
Studies and parts of the Institute For Genome Sciences And
Policy.” The idea, of course, is to leverage Duke’s ‘brain’
commitment through coordination. We would have to question, of
course, whether he will have the power and the will to hammer heads
together to achieve some common goals. The American intelligence
community, for instance, has nominally had some direction and
coordination since the creation of the CIA; but the intelligence units
in Government, particularly in the Defense Department, have very much
gone their own way. More importantly, we would suggest, the
disciplines being coordinated don’t have a wide enough compass.
Chemistry, for instance, has a great deal to do with real progress in
neuroscience, yet only a handful of brain scientists can find their way
around a molecule. (2/27/08)
245. How Brains Create New Cells
“Researchers at Sahlgrenska University Hospital in
Göteborg have discovered how stem cells produced in a ‘nursery’
deep inside the brain then migrate into other parts of the brain,
maturing into nerve cells on the way.” “Working with colleagues
from New Zealand, the Swedish researchers traced the pathway from the
subventricular zone deep within the brain (where neural stem cells are
created) to the olfactory bulb in the limbic system, where the stem
cells change into nerve cells.” See “Human Neuroblasts Migrate to
the Olfactory Bulb via a Lateral Ventricular Extension,” Science,
March 2, 2007, Vol. 315. no. 5816, pp. 1243-49. (2/13/08)
244. Fast Uppers
“A McGill University study has found that a new class of drugs known as
serotonin4 (5-HT4) receptor agonists may take effect four to seven
times faster than traditional selective serotonin reuptake inhibitors
(SSRIs). The study, led by former McGill post-doctoral fellow in
psychiatry Guillaume Lucas with his supervisor, the late Dr. Guy
Debonnel, was published in the September 6 issue of the journal Neuron”
(McGill University News Release, September 5, 2007). See “Serotonin4
(5-HT4) Receptor Agonists Are Putative Antidepressants with a Rapid
Onset of Action,” Neuron, September 6, 2007. “These
findings point out 5-HT4 receptor agonists as a putative class of
antidepressants with a rapid onset of action.” (1/30/08)
243. Loneliness Molecule
“Now, in the first study of its kind, published in the current issue of
the journal Genome Biology, UCLA researchers have identified
a distinct pattern of gene expression in immune cells from people who
experience chronically high levels of loneliness. The findings
suggest that feelings of social isolation are linked to alterations in
the activity of genes that drive inflammation, the first response of
the immune system. The study provides a molecular framework for
understanding why social factors are linked to an increased risk of
heart disease, viral infections and cancer.
Having previously established that lonely
people suffer from higher mortality than people who are not lonely,
researchers are now trying to determine whether that risk is a result
of reduced social resources, such as physical or economic assistance,
or is due to the biological impact of social isolation on the
functioning of the human body” (UCLA News Release, September 13,
2007). See “Social
Regulation of Gene Expression in Human Leukocytes,” Genome
Biology, Vol 8, Issue 9, R189. “Impaired transcription of
glucocorticoid response genes and increased activity of
pro-inflammatory transcription control pathways provide a functional
genomic explanation for elevated risk of inflammatory disease in
individuals who experience chronically high levels of subjective social
isolation.” (1/23/08)
242. Alzheimer's Drug Effectiveness
Jeffrey
L. Cummings is usefully focused, in our opinion, on the
effectiveness of the panoply of drugs coming to market for treatment of
Alzheimer’s. To wit, he indicates this is quite a challenge,
since some of the drugs being offered are only affecting symptoms of
the disease, and not modifying the structure and mechanism of the
disease. He has authored “Challenges to Demonstrating
Disease-Modifying Effects in Alzheimer’s Disease Clinical
Trials.” It is also useful to look at this editorial “Searching
for Methods to Prevent, Detect, and Treat Alzheimer’s Disease,” American
Journal of Psychiatry, April 2005, 645-647. Cummings head up
UCLA’s Alzheimer’s Disease Research Center, one of the larger programs
in the country. (1/2/08)
241. Shoring up the Brain
Many efforts are afoot to make the brain more resilient. “Duke
University chemists are developing ways to bind up iron in the brain to
combat the neurological devastation of Parkinson’s and Alzheimer’s
diseases. The key is to weed out potentially destructive forms of
iron that generate harmful free radicals while leaving benign forms of
iron alone to carry out vital functions in the body.” “The
pro-chelators that Franz described contain phenols that wear chemical
‘masks’ around themselves to keep them from binding with benign forms
of iron or other metals, such as those found in some essential
enzymes. But the presence of excessive amounts of hydrogen
peroxide will trigger an unmasking, allowing the phenols to sop up and
inactivate the bad iron.” See “A
Pro-Chelator Triggered by Hydrogen Peroxide Inhibits Iron-Promoted
Hydroxyl Radical Formation,” Journal of the American Chemical
Society, September 2006.
As well, researchers think they may have
developed a vaccine that can ward off brain tumors. “Duke
researchers are using a vaccine to hopefully prevent recurrence of the
most common and deadly type of brain tumors. As opposed to most
other cancer treatments, the vaccine does not have negative side
effects. So far, the trial has shown promising results.”
Duke and M.D.
Anderson researchers have held promising trials, though it’s not
certain whether chemo or the vaccine offer the best course of
treatment. (12/5/07)
240. Dopamine and ADHD
“A team led by Dr. Nora Vokow, director of the NIH’s
National Institute of Drug Abuse, documented decreased dopamine
activity in the brains of a group of adults with ADHD.” See the Wall
Street Journal, August 7, 2007, p. D3. “A second team..led
by Dr. Philip Shaw of the NIH’s National Institute of Mental Health
NIH’s National Insitute of Mental Health … used … MRI..exams to look at
the brain structure of children with and without ADHD.” See “Depressed
Dopamine Activity in Caudate and Preliminary Evidence of Limbic
Involvement in Adults With Attention-Deficit/Hyperactivity Disorder.”
In general, there is a need to study much more carefully the chemistry
behind various brain disorders. (11/14/07)
239. Gatekeeper
of the Mind
“Amy Arnsten, a medical school neurobiologist, has for the first time
isolated its molecular lock-and-key mechanism, gaining insight into one
possible cause of the cognitive deterioration associated with mental
illness and old age.” Exploring how guanfacine works which is
used to treat ADHD, she found that it “inhibited a brain messenger
called cyclic AMP. Cells in the prefrontal cortex “contain
gatekeepers called HCN channels… Cyclic AMP locks and unlocks these
channels.” When open, electric signals cannot be
transmitted. See Yale Alumni Magazine, July/August
2007, p. 25. See “Study
Offers Glimpse of Molecules that Keep Memories Alive,” NIMH, July
2, 2007. (10/17/07)
238. RNA Interference
“Tests of (a new) therapy at Harvard Medical School in Boston found
that a simple injection was able to cure mice of a potentially fatal
brain disease.” The hope is to do human trials in 5 years, with
the view of attacking a wide range of brain diseases. “The team
used a powerful new technique called RNA interference to silence faulty
genes or viruses that cause brain diseases. The principle of gene
silencing is simple: scientists build tiny strands of the genetic
material called RNA which, when injected into cells, latch on to
problematic genes and smother them, effectively shutting them
down.” See Harvard Medical Focus, March 10, 2006,
“RNA Sequence Restrains Fatal Encephalitis,” for more on this work
and on RNA interference.
“Therapies
based on RNA interference have become the next great hope for medicine,
and a large number are either in or about to start early clinical
trials in humans. The technique earned its discoverers, the US
researchers Andrew Fire and Craig Mello, the Nobel prize in medicine or
physiology last year.” See the Guardian, June 18, 2007,
p. 9. (10/10/07)
238. Dreams
Are Back
Dreams are back. Not the bountiful, exhilarating variety, but
rather the troublesome kind. Often they recapture people who have
passed away. “Big dreams are once again on the minds of
psychologists as part of a larger trend toward studying dreams as
meaningful representations of our concerns and emotions. ‘Big
dreams are transformative,’ Roger Knudson, director of the Ph.D.
program in clinical psychology at Miami University of Ohio, said in a
telephone interview. The dreaming imagination does not just
harvest images from remembered experience, he said. It has a
‘poetic creativity’ that connects the dots and ‘deforms the given,’
turning scattered memories and emotions into vivid, experiential
vignettes that can help us to reflect on our lives” (New York Times,
July 3, 2007).
“Deirdre
Barrett, assistant professor of psychology at the Harvard Medical
School and editor in chief of the journal Dreaming, wrote
the first significant study on dreams about the dead. She
collected dream reports from two sample groups totaling 245 people at
the University of North Carolina, Chapel Hill, and found 77 such
dreams. Her findings were published in the 1992 issue of Omega:
The Journal of Death and Dying. (10/3/07)
237.
Coping
with Brain Injury
Coma, a Liz Garbus documentary about brain injury from HBO, was
aired on July 3, 2007. “Ms. Garbus follows four patients at the Center for Head
Injuries at the John F. Kennedy Medical Center in Edison, N.J., in
the aftermath of devastating accidents…” (New York Times,
July 3, 2007, p. B10). The documentary follows the partial
recoveries of 4 patients from brain injury and the toll this process
takes on the patients’ families. “We learn the drastic
differences between a conscious state, a minimally conscious state and
a persistent vegetative state,” says Kevin McDonough of United
Features. (9/19/07)
236.
The
Ice Man Cometh
“Writing in the May Issue of Evolutionary Psychology, they
reported that volunteers yawned more often in situations in which their
brains were likely to be warmer” (New York Times, July 3,
2007, p. D6). Of course, we suspect anybody who has done basic
training in the Army could have saved Andrew Gallup, a psychology
prof at SUNY, Albany all the work and conjecture. The Army
runs you in the cold, then takes you into a small classroom that’s
plenty warm: you yawn bigtime. “The two conditions thought to
promote brain cooling (nasal breathing and forehead cooling)
practically eliminated contagious yawning.” In particular, when
participants were prompted to put an icepack on the forehead or to
breathe through the nose, continuous yawning halted. Mouth
breathing or warm packs had the opposite effect. Incidentally,
studied efforts at brain cooling—such as breathing—seem also to provide
relief to sufferers from a variety of neurological ticks such as OCD
and ADD, etc. See
“Yawning as a Brain Cooling Mechanism.” (9/12/07)
235.
Peptides
and Alzheimer’s
Researchers have found that a specific imbalance between two peptides
may be the cause of the fatal neurological disease that affects more
than five million people in the United States. “We have found
that two peptides, Aβ42 and Aβ40, must be in balance for normal
function,” said Chunyu Wang, lead researcher and assistant professor of
biology at Rensselaer. If correct, the addition of Aβ40 may stop
the disease’s development. These two peptides have been
previously found in deposits, called senile plaques or amyloid plaques,
in brains afflicted with Alzheimer’s disease. These plaques, mainly
composed of Aβ42 fibrils, are a hallmark of Alzheimer’s disease.
Using NMR data, Wang found that as Aβ40 levels increased, the
aggregation of Aβ42 fibrils sharply decreased, protecting benign Aβ42
monomers. Wang’s experiments show that when there is 15 times
more Aβ40 than Aβ42, the formation of Aβ42 fibrils is almost completely
stopped. See the
RPI News Release, May 29, 2007. (9/5/07)
234. Alzheimer’s
Markers
“Over the past two years, rival scientists in the U.S. and Europe have
identified a series of proteins, known as biomarkers, whose presence in
blood or spinal fluid may indicate whether a patient has Alzheimer’s,
the most common form of dementia” (Wall Street Journal, December
12, 2006, pp. D1, D4, and D5). As readers Brain Stem may have
surmised, the editors of this section are hardly enthusiastic about
pursuing a genetic and/or MRI track in researching neurological
complaints. However, we do believe this is the correct path for
detection and pre-detection of the several complaints of the
brain. Plenty of research papers have identified a host of
biomarkers for this disease. “In February, Swedish scientists
published a five-year study in the journal Lancet Neurology, describing
how the relative progression to Alzheimer’s disease … was significantly
increased if their spinal fluid contained abnormal amounts of the same
three biomarker proteins, known as b-amyloid, total tau and
phosphorylated-tau.” Researchers at King’s College in London have
discovered 15 biomarkers associated with
Alzheimer’s. Proteome Sciences and Nanosphere are both working the
marker problem. A
Cornell study has identified some 23 markers for the disease.
Biomarkers are
becoming all the rage, and new tests are springing up rapidly that
identify sundry diseases, particularly several forms of cancer.
But genetics is less successful at offering cures, once disease is
discovered. (7/11/07)
233.
Colleges—High Anxiety
The American College Health Association does surveys of student health
with some regularity, which it makes available in its National College
Health Assessments. We would caution readers to take these
results with a grain of salt, but nonetheless the trend is
unmistakable. Both stress and depression have risen considerably
over the last decade, both because of what student populations bring to
college and because of the atmospherics at colleges. When we
visit college health departments, we find that many have staffed up
considerably to handle mental and emotional problems, though we find
these mental health activities are not well administered and college
administrations are rather divorced from what goes in their health
departments. In the 2006 survey the Assessment covered
approximately 95000 students at 117 schools. Students reported
the following feelings at least once during the year: feeling
overwhelmed by what they had to do, 93.4%; feeling so depressed it was
difficult to function, 43.8%; contemplating suicide, 9.3%; feeling
exhausted, 91.5%. (7/4/07)
232. Stairmaster
Memory
Researchers may have established a direct connection between exercise
and memory maintenance as we grow older. “The researchers, led by
Dr. Scott A. Small, an associate professor of neurology at the
Columbia University Medical Center, looked at changes in the brains
of volunteers who worked out on exercise equipment. The
researchers were trying to confirm the findings of earlier research
they did involving mice. When the mice exercised, blood flow
increased to a part of the brain called the hippocampus, and more
specifically to the dentate gyrate. In post-mortems, the
researchers found evidence of neuron growth in the dentate gyrate.”
“But using 11 volunteers, an M.R.I. machine and equipment like
treadmills, the researchers were able to see whether blood flow
increased to the same part of the brain in humans as it had in mice.
It did, suggesting that working out may help produce neurons in a
part of the hippocampus that loses them disproportionately as people
age” (New York Times, March 20, 2007, p. D6).
Also see
“New Reason to Hit the Gym: Fighting Memory Loss,” press release of
Columbia University Medical Center, March 12, 2007.
“Exercise, the researchers found, targets a region of the brain
within the hippocampus, known as the dentate gyrus, which underlies
normal age-related memory decline that begins around age 30 for most
adults.” “Our next step is to identify the exercise regimen that
is most beneficial to improve cognition and reduce normal memory loss,
so that physicians may be able to prescribe specific types of exercise
to improve memory,” said Dr. Small, who is also a research scholar at
the Columbia University Taub Institute for Research on Alzheimer’s
Disease and the Aging Brain. (6/6/07)
231. NeuroLaw
Emerging theory about brain process and neurological development is
creating clouds and ambiguity for judges and eroding the givens of
legal process. Elizabeth Loftus, professor of psychology and
criminology at UC Irvine and Richard Steinberg, a Detroit lawyer,
challenge Judge Reggie Walton’s exclusion of expert testimony in the
Scooter Libby case in “If Memory Serves,” Wall Street Journal,
March 9, 2007, p. A14. Libby claimed, in defense, that bad
memory, not willful intent, caused him to make mistakes in his Grand
Jury testimony. The judge held, in the end, that memory ‘science’
is not really a science, using this reasoning to bar testimony from
Robert Bjork, also of UCLA.
Nonetheless,
Jeffrey Rosen—in “The Brain on the Stand,” New York Times Magazine,
March 11, 2007, pp. 48 and following—makes clear that the use of expert
witnesses and brain imaging studies is on the rise throughout
courtrooms, with one Florida court even saying that the failure to
admit neuroimaging evidence during capital sentencing may create
grounds for reversal. This wordy article does not merit a full
reading, but it does let us know a new trend is in the making.
(5/30/07)
230.
Good
Bacteria
The presence of certain kinds of bacteria may, in fact, lower
depression. Mary O'Brien, an oncologist at the Royal Marsden
Hospital in London, tried out “an experimental treatment for lung
cancer that involved inoculating patients with MYCOBACTERIUM
VACCAE. This is a harmless relative of the bugs that cause
tuberculosis and leprosy that had, in this case, been rendered even
more harmless by killing it. When Dr O'Brien gave the
inoculation, she observed not only fewer symptoms of the cancer, but
also an improvement in her patients’ emotional health, vitality and
general cognitive function” (Economist, April 4, 2007).
Chris Lowry of Bristol University has further investigated this
phenomenon. Experimenting with mice, he found that cytokine
levels rose, which in turn could act on sensory cells which in turn
release serotonin. This offers the intriguing possibility of
treating depression with bacteria and, further, it may explain the rise
of certain diseases which may flourish in the absence on myco-vaccae.
See Journal of Neuroscience. (5/23/07)
229.
Second
Generation Atypicals (SGA)
A host of commentary on both sides of the Atlantic has boiled up about
second generation anti-psychotics. Many researchers have been
working this problem, wondering about their effectiveness, costs, and
risks. There’s at least a consensus now that second generation
are no more effective, and maybe less effective, than first
(FGA). Some believe second-generation drugs demonstrate more
dangerous side effects. Some of the NIH studies emphasize that
the newer drugs inflict huge costs without any commensurate upside.
One popular treatment of this subject “In Antipsychotics, Newer
Isn't Better: Drug Find Shocks Researchers,” Washington Post,
October 3, 2006, p. A1 summarizes a
British study led by Peter Jones of Cambridge University concluding
that “schizophrenia patients do as well, or perhaps even better, on
older psychiatric drugs compared with newer and far costlier
medications.” Jeffrey Liebermann of Columbia and others have been
directing subsequent very broad NIH studies that apparently reach
much the same conclusion. Separately, of course, it has been
noted that no really good drug for schizophrenia has come on the
market, and that a whole raft of supportive treatment mechanisms are
still state of the art for its treatment. (5/16/07)
228.
Schizophrenia Algorithms
Vanderbilt University has furthered advanced algorithms used in
schizophrenia treatment Earlier work headed by Dr. Kenneth Jobson had
already paved the way with some successes on medication regulation.
In 2000 Dr. Herbert Meltzer of Vanderbilt joined the effort.
A new Web-based tool is now available to help clinicians
determine the best medication for patients with schizophrenia. An
international team led by Meltzer completed the new algorithms, or
step-by-step protocols, in late 2004 to provide clinicians with help on
their treatment decisions. Meltzer speculated that following the
algorithms could save up to 40% of drug costs and give practical
guidance to those who don’t fully know the literature or who cannot
spend much time with patients. Further it was thought that
controlling polypharmacy would improve patient outcomes. The
literature, however, continues to reveal problematic results with
schizophrenia drug treatments. See our entry on “Second
Generation Atypicals (SGA).” (5/9/07)
227.
Learning
While You Sleep
Max Planck researchers in Heidelberg are investigating communication
between memory areas during sleep. Their study offers the
hitherto strongest proof that new information is transferred between
the hippocampus, the short term memory area, and the cerebral cortex
during sleep. It has been difficult up to now to use experiments
to examine the brain processes that create memory. The scientists
in Heidelberg developed an innovative experimental approach especially
for this purpose. They succeeded in measuring the membrane
potential of individual interneurones (neurones that suppress the
activity of the hippocampus) in anaethetised mice. At the same
time, they recorded the field potential of thousands of nerve cells in
the cerebral cortex. This allowed them to link the behaviour of
the individual nerve cells with that of the cerebral cortex. The
researchers discovered that the interneurones they examined are active
at almost the same time as the field potential of the cerebral cortex.
There was just a slight delay, like an echo. Thomas Hahn,
Bert Sakmann & Mayank R. Mehta, “‘Phase-locking of hippocampal
interneurons’ membrane potential to neocortical up-down states,”
Nature Neuroscience. (5/2/07)
226. Cornelia
deLange Syndrome (CdLS) and Retardation
Ian D. Krantz at Children’s Hospital in Philadelpha has long been
at work uncovering the genetic apparatus behind Cornelia deLange
syndrome, a multisystem geneticdisease that affects an estimated one in
10,000 children. In 2004 a team led by him learned that the NIPBL
gene caused mutations in roughly half of known CdLS cases. In the
present study, Dr. Krantz and Dr. Laird Jackson of Drexel University
found that mutations in two other genes, SMC3 and SMC1A, cause
about 5 percent of CdLS cases. But the two new genes, as well,
look more generally to be a pathway to mental retardation. “In
these cohesin complex proteins, the strongest effect seems to be in
brain development,” said Dr. Krantz.
Drs. Krantz and
Jackson together maintain the world’s largest database of patients with
CdLS. The current study screened 115 patients who did not have
mutations in the NIPBL gene, but who were judged to have CdLS or a
milder variant of the disease, based on evaluations by clinical
geneticists. “Gene Found for Rare Disorder May Reveal New Pathway
in Mental Retardation,” Press Release, Children’s Hospital of
Philadelphia, February 5, 2007. For abstract, see the
American Journal of Human Genetics. (4/25/07)
225. Chewing
Gum and Walking
Lyndon Johnson said that Gerry Ford couldn’t chew gum and walk at the
same time. But it turns out that multi-tasking is pretty darn
hard for everybody. Paul E. Dux and René Marois at
Vanderbilt have found that when it comes to handling two things at
once, your brain, while fast, isn’t that fast. See “Neural
bottleneck found that thwarts multi-tasking,” Vanderbilt University
Press Release, January 18, 2007. Their research revealed that the
central bottleneck was caused by the inability of the lateral frontal
and prefrontal cortex, and also the superior frontal cortex, to process
the two tasks at once. Both areas have been shown in previous
experiments to play a critical role in cognitive control. “Neural
activity seemed to be delayed for the second task when the two tasks
were presented nearly simultaneously – within 300 milliseconds of each
other,” Marois said. See Neuron, vol. 52, pp. 1109-1120,
21 December 2006. (4/18/07)
224. Addiction
Central
“Damage to a silver-dollar sized spot deep in the brain seems to wipe
out the urge to smoke.” Known as the insula, scientists theorize
that is the brain center for addiction. “The insula seems to be
where the brain turns physical reactions in to feelings,” so it appears
to act as a headquarters for cravings. Research on the insula,
funded by the NDA, was led by Dr. Antoine Bechara at the University of
Southern California. See WSJ, January 26, 2007, p.
B5. Also see “Damage to
Specific Part of the Brain May Make Smokers ‘Forget’ to Smoke,” NIH
News Release, January 25, 2007. (3/28/07)
223. The
Phobias of Allan Shawn
“As he notes in his remarkable new memoir,
Wish I Could Be There, the composer Allen Shawn suffers from a
veritable rainbow of phobias: ‘In probing the consequences and possible
causes of his phobias, Mr. Shawn has written a brave, eccentric and
utterly compelling book that’s as revelatory and candid as anything
ever written by Joan Didion, and as humane and scientifically
fascinating as any one of Oliver Sacks’s case studies.” See
“Recalling a Literary Family, and Phobias,” New York Times,
January 30, 2007. Son of William Shawn, longtime editor of the New
Yorker, and brother of Wallace Shawn, the actor, Shawn attributes
some of his tortures to separation from his autistic sister Mary at an
early age. “These fears amplified his own ‘terror of mental
illness’—the fear that, being Mary’s twin, he too was somehow damaged
or different.”
“In addition,
the Shawn household, with its emphasis on discretion and denial, seems
to have been an “incubating environment” for future phobias, a petri
dish of unspoken emotions. The author’s father carried on a
four-decade extramarital affair, and his reticence about his
complicated double life (“it wasn’t uncommon for him to eat, or at
least, attend four or even five meals a day to accommodate all the
important people in his life”) created an atmosphere in which secrecy
and repression flourished.” (3/21/07)
222.
Brain on Brain
Sharon Begley, science columnist at the Wall Street
Journal, has a book out
Train Your Mind, Change Your Brain. In a January 19
column in the WSJ, she does a column of snippets from the new
book. We know, she says, that the body’s chemistry and physics
acts on the brain. The Dalai Lama wondered if the reverse were
true. “Could it work the other way around? That is, in
addition to the brain giving rise to thoughts and hopes and beliefs and
emotions that add up to this thing we call the mind, maybe the mind
also acts back on the brain to cause physical changes in the very
matter that created it. If so, then pure thought would change the
brain's activity, its circuits or even its structure.” “But the
brain changes that were discovered in the first rounds of the
neuroplasticity revolution reflected input from the outside world.
For instance, certain synthesized speech can alter the auditory
cortex of dyslexic kids in a way that lets their brains hear previously
garbled syllables; intensely practiced movements can alter the motor
cortex of stroke patients and allow them to move once paralyzed arms or
legs. The kind of change the Dalai Lama asked about was
different. It would come from inside.” “Cognitive-behavior
therapy muted overactivity in the frontal cortex, the seat of
reasoning, logic, analysis and higher thought. The antidepressant
raised activity there. Cognitive-behavior therapy raised activity
in the limbic system, the brain’s emotion center. The drug
lowered activity there. With cognitive therapy, says Dr. Mayberg
[Helen Mayberg of the University of Toronto], the brain is rewired ‘to
adopt different thinking circuits.’” “The discovery that
neuroplasticity cannot occur without attention has important
implications. If a skill becomes so routine you can do it on
autopilot, practicing it will no longer change the brain. And if
you take up mental exercises to keep your brain young, they will not be
as effective if you become able to do them without paying much
attention.” (3/14/07)
221.
Amnesia
and the Future
We have long known that damage to the hippocampus
produces loss of past memories, a condition to which we apply the term
‘amnesia.’ But the losses of amnesia are much greater, limiting
the afflicted’s ability to see or imagine the future. Eleanor
McGuire and her associates at the Wellcome Trust have long been
exploring this very territory. Now Karl Szpunar and colleagues at
Washington University in St. Louis have published on how the ‘imaging’
mechanism works. Their article “Imaging pinpoints brain regions
that “see the
future” summarizes sum of the study’s conclusions, which are
published online by the National Academy of the Sciences:
Our
findings provide compelling support for the idea that memory and future
thought are highly interrelated and help explain why future thought may
be impossible without memories.
The
study clearly demonstrates that the neural network underlying future
thought is not isolated in the brain’s frontal cortex, as some have
speculated. Although the frontal lobes play a well-documented
role in carrying out future-oriented executive operations, such as
anticipation, planning and monitoring, the spark for these activities
may well be the very process of envisioning oneself in a specific
future event, an activity based within and reliant upon the same
neurally distributed network used to retrieve autobiographical
memories.
Second,
within this neural network, patterns of activity suggest that the
visual and spatial context for our imagined future often is pieced
together using our past experiences, including memories of specific
body movements and visual perspective changes—data stored as we
navigated through similar settings in the past.
220.
Plaque
Busters
For several years, dedicated neuroscientists, well apart
from the crowd, have been telling us the plaque does not tell the story
for Alzheimer’s. Sharon Begley, author of one of the better
columns in the Wall Street Journal, has touched on this and,
lately, has delivered two salvos making this point, both on November 17
and November 24:
As
I described
last week, the belief that amyloid plaques are the chief cause of
this disease so dominated Alzheimer’s research that it became
“orthodoxy,” says Zaven Khachaturian, who oversaw Alzheimer’s funding
at the National Institute on Aging from 1977 to 1995. “Having one view
prevail is harmful; it becomes a belief system, not science.”
Orthodoxy
also stifles research on other culprits. “Where the field made its
mistake was in trying to make everything fit one common [amyloid]
pathway,” says Robert Mahley, president of the J. David Gladstone
Institutes, San Francisco. “We've got to realize there are multiple
ways you can wind up with [Alzheimer’s].”
She goes on to mention a few of
the enzyme and gene theories that may shed some light on the
disease. What she makes clear and what we should understand is
that standard orthodoxy has slowed discovery on this fast-spreading
disease. We are particularly aware of research that has been
shoved aside in the Boston medical community, but a similar lack of
open-mindedness has shut down innovative thinking in many other ports
of call. When we asked one researcher in the South what he
thought of a particular line of thinking that looked hard at brain
chemistry, he said, “We don’t get into offbeat things like that.
We can’t get any Government funding for anything out of the
mainstream.”
The Economist (July 29,
2006, pp. 71-72) looks at the dimensions of the problem and the lack of
progress. “At the moment, 4.5 million Americans have Alzheimer’s.
By 2050 … that number will have trebled.” Plaques (beta and
tangles) are still the key manifestations of the disease and, hence,
the central focus still in investigations. There are a host of
attempts to slow the progress of the disease, some of which we have
enumerated in “New
Strategies for Blocking Alzheimer’s.” This is only one field
where lockstep thinking is slowing scientific discovery. (2/28/07)
219.
Use It or Lose It
“Keeping mentally agile protects against dementia but until now no one
has known exactly why” (Economist, October 21, 2006, p. 91).
Rats, it is revealed, grow thousands of brain cells every day,
but only retain them if used; otherwise, they die off in a couple of
weeks. For the longest while scientists thought that we did not
grow new cells—that we only had those with which we came to this
party. But now they know we grow a lot, many in the hippocampus,
the center for remembering events. Tracey Shors of Rutgers and
her colleagues found that neurons are retained if used, and, maturing,
get wired into networks if they are involved in complex learning
chores. For more on this, see the vita of Dr.
Shors. There is still considerable dispute, however, as to what
extent brain exercise helps deteriorating brains. (2/21/07)
218.
Chemo Hurts
We are intimately familiar with cancer survivors who say that their
brains are very, very cloudy for about a year after their last
intravenous feed by the oncologists. Now researchers have come
along to prove the obvious. “Researchers at the University of
California, Los Angeles, took PET scans of the brains of 34 women as
they performed short-term memory tests. Those who had received
chemotherapy five to 10 years earlier required significantly more blood
flow in a region associated with short-term memory than healthy women
or those who only had surgery to treat the cancer” (Boston Globe,
October 9, 2006, pp. C1-2). “No therapy is currently proven to
prevent or treat chemo brain, though ongoing clinical studies are
testing ginkgo biloba and Alzheimer’s therapies as potential
remedies….” See Neurology
Reviews.com. (2/14/07)
217.
Post-Prozac Depression Drugs
Pfizer, Sanofi-Aventis, and others “are targeting a system of brain
chemicals that are involved in the body’s response to stress.”
See “Targeting Depression,” Wall Street Journal, December 14,
2006, pp. B1 and B6. These include Bristol’s CRF 1 Antagonist,
Novartis Agomelatine, Novartis Metabotropic glutamate receptor 5
Antagonist, and Concept’s Mifepristone. Existing remedies only
help half of all depression patients and often have unpleasant side
effects. They target neurotransmitters, acting on proteins from
only about 20 of the approximately 15,000 genes in the brain. “Part of
the problem is that the biology of depression isn’t well understood,
even compared with other psychiatric diseases.” Stress, it seems,
ultimately leads to the production of CRF, leading to release of
hormones including cortisol that seems to induce depression.
Cortisol may damage nerve cell connections and prevent nerve
growth. Targacept is studying mecamylamine, a blood pressure drug
it got from Merck, seeing whether it will block receptors and control
mood fluctuation. As usual, there is the threat of side effects,
particularly to the liver. (2/7/07)
216.
3
Lbs.
CBS is out with a new TV drama about—of all things—brain surgeons.
It stars the fabulous Stanley Tucci, but it already may be
terminal. The Boston Herald says, in a
review echoed by many others, that it “needs some medical
help.” Dr. Hanson (Tucci) is brainy, talented, and, of course,
fouled up. He suffers from hallucinations, but we think the
writers are just projecting their own complaint onto their main
character. Associated Content notes: “The series takes
place in a cutting-edge[,] fantastically chic neurological surgical
facility in New York City. Apparently the drama of brain surgery
itself was not complex enough for the show’s producers, so they set the
two main characters, Dr. Hanson and Dr. Seger, against each other with
diametrically opposed philosophies about how to approach their
patients. At least the writers have infused the drama with a
touch of humor to break up all the staring at brain x-rays. The entire
neurological wing of the hospital is decorated with the pattern of
nerves that map the brain. They’re on the walls, on the rugs,
even on the privacy curtains. It makes for a busy background.”
You know, the neurosurgeons and neurologists we know are pretty
entertaining and don’t require all this made-up makeup. Too bad
CBS tarted it up. (1/17/07)
215. Cognitive Decline
Sharon Begley points out that we can get rather muddled about what
produces brain decline (Wall Street Journal, April 28, 2006, p.
B1). Many think that those in brain-active jobs ward off
dementia; more likely, says Ms. Begley, they have well-fortified brains
in the first place, and that they are armored against decline.
Mental exercise does not necessarily correlate with mental
preservation, despite the games dreamed up by neurologists and others
to keep you humming—many of which are mentioned on Global
Province. So one should approach MindFit from Israel, Nintendo’s
Brain Age, and My Brain Trainer with a grain of salt. They only
seem to help the brain along if you keep upping the ante, challenging
the mind with tougher and tougher mental exercises. Begley notes
that other forms of training—cardiovascular fitness exercise, for
instance—do seem to tune up the brain at the same time.
Merzenich, out in San Francisco, whom we discussed in “Old Brains
Don’t Die; They Just Fade Away,” offers data suggesting his system
may—we stress may—offer more enduring effects. (1/10/07)
214. Off-Label
Alzheimer’s Drugs
Gradually, more tentative drug approaches to Alzheimer’s are
emerging. We have previously discussed this in “Enhancers and
Inhibitors.” Drugs originally approved for diabetes,
prostate-cancer, and anti-inflammation are now in late stage trials for
Alzheimer’s. See the Wall Street Journal, October 17,
2006, pp. D1 and D2. “The four drugs currently approved …
Aricept, Exelon, Razadyne, and Namenda … are a huge business,” but they
really only relieve symptoms and do not treat the underlying mechanism
of the disease. “Some of the most promising results to date
involve Flurizan, which is derived from an anti-inflammatory and is
being tested by Myriad Technologies. The drug targets an enzyme, called
gamma secretase, that is believed to play a role in the build-up of
amyloid.” “Researchers also tout Alzhemed, a drug being developed
by a Canadian company, Neurochem Inc….” It has stabilized the
condition for long periods of time in a number of patients.
(12/13/06)
213. Narcolepsy
Either one gets too much sleep or no sleep at all. We are just
beginning to take a look at Narcolepsy. For starters, we will
recommend Stanford’s Center for Narcolepsy. (Somehow this reminds
us that the people at UC Berkeley used to say, “There are some bright
people down at Stanford. But they have baked brains.” Maybe
so). We find its
historical material a little useful, though we are not able to
evaluate its focus on hypocretins. We would, of course, like to
see more research on the site from other institutions. It
probably helps to look at the Narcolepsy Network
in order to get a wider scan of the field. We are bemused by the Sleep Foundation’s site.
You can look into the Midwest’s view of the problem at the University of
Illinois-Chicago Center for Narcolepsy. (11/22/06)
212. Chez
Scaruffi
You cannot be in the brain business and fail to look at
Piero Scaruffi. He is perhaps most renowned for his music site but Thymos is a must for anyone
who wants to think about cognition. We have just begun to explore
it. Perhaps a good starting point is his Annotated Bibliography of the
Mind, which covers a fair patch of the literature on
consciousness. He’s a poet and freelance critic as well. If
you need to get away from his catalog of cognition, visit his cluster
of other sites and strands.
211. Tuning Up
the Brain with Sleep
At a recent meeting of “the Organisation for Human Brain
Mapping in Florence, Italy, Giulio Tononi of the University of
Wisconsin theorized that after extensive learning the brain grows
increasingly inefficient. “Sleep prunes back the grey matter so
that, come the morning, the brain is once again economical to
run. If this pruning cannot take place, the organ becomes less
and less efficient, and dire consequences result.” See “The Big
Sleep,” Economist, July 8, 2006, pp.73-74. Indeed, this
proposition supports the notion we put forward in “The Big
Sleep” that the exhaustive regimen schools are now inflicting on
our kids is a clear impediment to learning.
“Even at rest, the brain is
costly to run, consuming 20% of the body’s energy production.”
Traditionally sleep researchers have focused on REM sleep which only
comprises only 20% of a night’s store. But actually brain
restoration seems to take place during the other 80% that we have not
examined so closely. The slow waves that sweep across the brain
during this period are thought to tone down the synapses that are
forged and expand during the day—“reducing their size, chemical
activity and electrical activity….”
“The researchers’ discovery
finds an intriguing echo in a human disease called Morvan’s
syndrome. This is a rare brain disorder that is caused by an
autoimmune response which destroys the human equivalents of ion
channels that are affected in the mutant fruit fly. Patients with
Morvan’s syndrome suffer from severe insomnia and have been known to go
for months without sleeping. Eventually, this extreme sleep
deprivation kills them.”
The theory is
controversial, however, since many have held that sleep buttresses the
synapses, rather than getting them to pull back. (11/1/06)
210. Parasites
and Brain Development
Fred Gage of the Salk Institute thinks that brain junk in the DNA—the
95% that is not genes—may play a part in brain development. See
the Economist, June 18, 2005, pp.76-77. “One of
the most puzzling sorts of junk, though, is something known as Line-1
retrotransposon.” Resembling retroviruses, they jump from
chromosome to chromosome. Generally, it makes up 20% of the human
genome. Some, “instead of being destroyed … have been subverted …
to create complexity in the brain,” theorizes Gage. They are
active in “precursor cells,” altering the course of cell development.
For more, see “Jumping
Genes.” (10/25/06)
209. Parenting
Rewires the Brain
“Fatherhood increases the nerve connections in the region of the brain
that controls goal-driven behaviour—at least, it does in marmosets.”
It has long been known that it causes changes in females, causing
a greater number of neural connections. Elizabeth Gould of
Princeton did research in this specific area, and allied research has
been done by Craig Kinsley at University of Richmond. See
Nature, 24 August 2006, pp. 850-51. (10/18/06)
208. Electro-Shock
Electric shock treatments are being selectively revived. See the
Economist, June 3, 2006, pp. 78-79. “Vagus-nerve stimulatin …
was originally developed to treat severe epilepsy.” Even where it does
not lessen number of seizures, epilectics “reported feeling much better
after receiving the implant.” This has led to its application in
depression and in 2005 the FDA approved it for use where all else
fails. Its effects are reported to be long lasting. It
builds on the idea of deep-brains stimulation which is a more
complicated procedure, the vagus insert being much easier to do.
It does, however, require a fairly long course of treatment—at
least 3 months-for the palliative effects to take hold. (10/11/06)
207. Fifty-Percent Cuts in
Brain Injury Funding
House and Senate bills prospectively will cut funding for the Defense
and Veterans Brain Injury Center from $14 million to $7 million.
The Pentagon had only asked for $7 million and has not been responsive
to Congress when asked whether it needed more. The Defense
Department has put a blanket on its staff, preventing it from
commenting on the issue. Officials at Walter Reed, where the
center is located, had indicated they needed $19 million to handle
rising case loads. It is our understanding that Senators Dick
Durban and George Allen are separately plumping for a richer
budget. See the daily.cos
for September 5, 2006. (10/4/06)
206.
Stuttering
We receive
reports of some modest progress on stuttering. Like autism and
many other neurological complaints, it is no longer regarded as an
environmentally induced form of behavior, but instead is taken to be
genetic and neurological in nature. In “To Fight Stuttering,
Doctors Take a Close Look at the Brain,” New York Times,
September 12, 2006, pp. D1 and D6, various hypotheses and possibilities
are forwarded. “Dr. Maguire, a psychiatrist at the University of
California, Irvine, wants to cure the ailment that afflicts him and an
estimated three million Americans.” Indevus Pharmaceuticals
announced in May encouraging results from a large clinical trial with
its drug pagoclone. “Men who stutter outnumber women by a ratio
of about 4 to 1, for reasons not known.” “Brain imaging studies
have shown that the brains of people who stammer behave differently
from those of people who don’t when it comes to processing
speech.” For non-stutterers speech processing is a left brain
activity. Stutterers, on the other hand, show an unusually large
amount of right brain activity. Because of a heavily afflicted
family in the Cameroons, Dennis Drayna, at the National Institute on
Deafness and Other Communiccation Disorders, has narrowed the genetic
search to “a stretch of Chromosome 1 containing 50 to 60 genes.”
“Another study using families from Pakistanwith large numbers of
stutterers found a region on Chromosome 12….” Some stutterers
have been helped by devices, such as SpeechEasy, a feedback mechanism
costing about $5,000 from Janus Development Group of Greenville, North
Carolina which feeds the speaker’s voice back to him with a slight
delay in a different pitch: the choral effect helps the
stutterer. Maguire has also done small trials with two
schizophrenia drugs, Risperdal and Zyprexa. (9/20/06)
205.
Half of a Brain
There is an outpouring of literature on hemispherectomy,
most recently in “The Deepest Cut,” New Yorker, July 3,
2006. “The first recorded hemispherectomy was performed, in 1888,
on a dog by Friedrich Goltz, a prominent German physiologist.
(Apparently, the post-op animal exhibited the same personality
and a minimal reduction in intelligence.) In humans, the
operation was pioneered by Walter Dandy, a Johns Hopkins neurosurgeon,
who, in 1923, performed his first hemispherectomy on a patient with an
aggressive brain tumor in the right hemisphere” “The
hemispherectomy’s resurgence in popularity is largely the work of John
Freeman, a pediatric neurologist who has been at Johns Hopkins nearly
his entire career.” “If Freeman revived the practice of
hemispherectomies, their leading practitioner has been Ben Carson, who
joined Johns Hopkins in 1984 and, at thirty-two, became the youngest
head of pediatric neurosurgery in the nation.” “Carson has now
performed more than a hundred hemispherectomies. One of his oldest
patients had the surgery in his thirties.”
“The brain’s remarkable
capacity for recovery has long fascinated scientists. Bradley
Schlaggar, a pediatric neurologist and a professor at Washington
University in St. Louis, told me about an experiment that he conducted
for his Ph.D. He transplanted the visual cortex from an embryonic
rat’s brain into the brain of a newborn rat, placing it in the spot
occupied by the somatosensory cortex, which is responsible for such
bodily sensations as pressure and temperature. Once the second
rat had grown up, Schlaggar took a look at its brain and discovered
that the transplanted chunk of visual cortex was functioning as a
somatosensory cortex.”
As remarkable
as the John Hopkins account in the New Yorker is
Half a Brain Is Enough: The Story of Nico. Here, “Antonio
Battro, a distinguished neuroscientist and educationalist, describes
his work with Nico over several years and explains how a boy with only
half a brain has developed into a bright child with relatively minor
physical and mental impairment.” Half the story is that the
brains of both children and adults can be removed, and that the
patients survive. The other half of the story is that they
survive so well: somehow half the brain fills in for the half that’s
been removed, with broad functionality returning to the patient, such
that the recovering patient in time can drive cars, learn, and
undertake a reasonably normal lifestyle. (9/13/06)
204.
Death of Eric Schopler
Eric Schopler,
an autism pioneer, died on July 7, 2006. Rejecting Bettleheim,
who tended to think autistic children were the products of untoward
parenting, he recognized it as a specific brain disorder. More
importantly, we think, he developed the TEACCH program in North
Carolina which, starting in 1966, helped parents and caregivers by
understanding that autistics did not learn in traditional ways but
could develop, especially with carefully designed interventions by
parents and others. Needless to say, he is represented on every
serious reading list about autism, such as Teaam’s in
Mississippi. (8/30/06)
203.
Update on Huntington’s Disease
“Huntington’s disease (HD) is an inherited neurodegenerative
disorder caused by an expanded CAG repeat in the gene coding for a
protein called huntingtin. George Huntington was the first to
describe the disease in his paper On Chorea, which was published in
1872.” “Approximately 1 out of 10,000 people in the United States
have HD.” “Petersen et al. (1998) proposed four models of neuron
loss in HD: excitotoxicity, oxidative loss, impaired energy metabolism,
and apoptosis.” “The two studies mentioned in detail above
concerning potential treatments for HD contribute to the understanding
of the pathological mechanism of the disease. Although cystamine
treatment rescued neuron loss in the striatum of the HD animal model,
motor function did not improve. However, gene silencing was able to
restore motor recovery without rescuing striatal neuron loss.
These results indicate that the abnormalities of motor function seen in
HD are due to neuronal dysfunction, and not necessarily neuron loss.”
See “Recent Advances Regarding Striatal Vulnerability and
Treatment of Huntington’s Disease,” The Washington and Lee Journal
of Science, Winter 2006, pp 5-8.
202. Spontaneous Re-Wiring
“Doctors Say Man’s Brain Rewired Itself,” Associated Press,
July 3, 2006. “The research on Wallis, published Monday in the Journal
of Clinical Investigation, was led by imaging expert Henning Voss
and neurologist Dr. Nicholas Schiff at the Weill Medical College of
Cornell University in New York City and included doctors at JFK Medical
Center in Edison, N.J. Wallis was 19 when he suffered a traumatic
brain injury that left him briefly in a coma and then in a minimally
conscious state, in which he was awake but uncommunicative other than
occasional nods and grunts, for more than 19 years.” Finally he
is more in touch with the world and able to carry on minimal
functions.
“‘The nerve
fibers from the cells were severed, but the cells themselves remained
intact,’ unlike Schiavo, whose brain cells had died, said Dr. James
Bernat, a neurologist at Dartmouth-Hitchcock Medical Center in New
Hampshire, who reviewed the research.” For a long, personal
account of all the Wallis family has experienced, read “Mute for 19
Years, He Helps Reveal Brain’s Mysteries,” New York Times, July
4, 2006, pp1ff. For an abstract of “Tracking the Recovery of
Consciousness from Coma,” see the Journal of
Clinical Investigation, July 3, 2006. Again and again, we
are learning that nerve cell regeneration is possible, although we do
not understand its mechanism. As well, the brain has shown
marvelous recuperative powers, restoring functionality even when large
parts of it are cut away. (8/16/06)
201.
Deja Vecu
A variant of déjà vu has given researchers a
more complex understanding of the memory mechanism. Called “deja
vecu,” a term coined by Swiss psychologist Art Funkhouser, a it
describes a condition where certain subjects experience the sensation
of déjà vu, of having seen something before, when they
meet some phenomena which they could not have previously
encountered. See The New York Times, July 2, 2006, pp.
38-43.
Canadian psychologist Endel
Tulving had previously broken memories into two categories—episodic and
semantic. Semantic broadly relates to the idea of recalling a
piece of data we have committed to memory. Episodic is when “we
actually re-experience the events themselves,” reliving some experience
that we went through before. Episodic memories are more complex, using
different parts of the brain, to conjure up memory but also to
interpret it as something we have experienced.
Chris Moulin at Leeds
University and, earlier, David Schacter of Harvard both had reported on
individuals who felt strongly familiar with people, newspaper accounts,
and other subject matter with which they had no possible
connection.
“Alan Brown, a psychologist at
Southern Methodist University and and the author of The
Déjà Vu Experience, the most comprehensive book
on the topic,” thinks about 2/3 of the population experience feelings
of déjà vu at one time or another.
“Brain scans of” those
experiencing deja vecu “revealed abnormal levels of atrophy, or cell
death, in their temporal lobes. Moulin knew that epilectics whose
seizures centered in their temporal lobes often experience a
minutes-long ‘dreamy state’ similar to déjà vu prior to
their seizures. Moulin and Conway concluded that … the deja vecu
of their patients was similarly located in the temporal lobes….
If the circuit was ‘continuously active,’ it would keep feeding the
brain that feeling of recollection, without any real memory
attached.” (8/9/06)
200.
Brainstorming B.S.
Most of these
sessions don’t work. People are erratic: they cannot suddenly
open their creative floodgates at a scheduled meeting. Some claim
“brainstorming sessions come in handy to distribute blame in the event
of failure.” See “Brainstorming Works Best if People Scramble for
Ideas on Their Own,” Wall Street Journal, June 13, 2006, p.
B1. “The popularity of brainstorming results in part from corporate
America’s knee-jerk faith in teams.” “Typically, group
brainstormers perform at about half the level they would if they
brainstormed alone.” (8/2/06)
199.
Keenly Impaired
“People with
schizophrenia see more clearly by ignoring visual context” (The
Economist, October 29, 2005, p. 84). “A team of researchers
led by Steven Dakin of University College London set out to find a test
in which schizophrenia sufferers would do well.” Schizoids tend to
perform poorly on almost any test. Presented with a visual
illusion, chronic schizophrenics could see much more clearly than a
control group of normally functioning people. “This might be part
of a more general failure to deal appropriately with context.”
“The research seems to confirm the guess of Dr. Beuler (the Swiss
psychiatrist who coined the schizophrenia term in the first place), who
described schizophrenia sufferers as ‘flooded with an undifferentiated
mass of incoming sensory data.’” We would further note for
researchers that there are a variety of conditions, going well beyond
schizophrenia, where the sufferers show visual dexterity that puts
ordinary mortals to shame. (8/2/06)
198.
ReProgramming the Brain
“I was lying on
my back in a large white plastic f.M.R.I. machine that uses ingenious
new software, peering up through 3-D goggles at a small screen. I
was experiencing a clinical demonstration of a new technology—real-time
function neuroimaging—using in a Stanford University study, now in its
second phase, that allows subjects to see their own brain activity
while feeling pain and to try to change that brain activity to control
their pain” (Melanie Thernstrom, “My Pain, My Brain,” The New York
Times Magazine, May 14, 2006, pp. 50-55). “Unlike acute pain,
chronic pain is now thought to be a disease of the central nervous
system that may or may not correlate with any tissue damage but
involves an errant reprogramming in the brain and spinal cord.”
“Rather, pain is a complex, adaptive network involving 5 or 10
areas of the brain transmitting information back and forth.”
There are pain-perception and pain-modulation systems—chronic
pain seems to come from overactive perception or dormant modulation.
“The area of the brain that the scanner focuses on is the rostral
anterior cingulated cortex (rACC) … [which] plays a critical role in
the awareness of the nastiness of pain.” (7/19/06)
197. Sound Algorithm
“Humans have 200 million light receptors in their eyes, 10
to 20 million receptors devoted to smell, but only 8,000 dedicated to
sound. Yet despite this miniscule number, the auditory system is
the fastest of the five senses. Researchers credit this
discrepancy to a series of lightning-fast calculations in the brain
that translate minimal input into maximal understanding.”
“Marcelo Magnasco … has published a paper that may prove to be a
sound-analysis breakthrough, featuring a mathematical method or
‘algorithm’ that’s far more nuanced at transforming sound into a visual
representation than current methods. ‘This outperforms everything
in the market as a general method of sound analysis,’ Magnasco
says.”
“The
applications are immense, and can be used in most fields of to pick up.
Radar and sonar both depend on this kind of time-frequency
analysis, as does speech-recognition software. Medical tests such
as electroencephalograms (EEGs), which measure multiple, discrete
brainwaves use it, too. Geologists use time-frequency data to
determine the composition of the ground under a surveyor’s feet, and an
angler’s fishfinder uses the method to determine the water’s depth and
locate schools of fish. But current methods are far from exact,
so the algorithm has plenty of potential opportunities.” See Rockefeller
University News Release, June 7, 2006 and
Proceedings of the National Academy of Sciences 103 (16):
6094-6099 (April 18, 2006). (7/12/06)
196.
Minimally Invasive Brain Surgery
“Aneurysms, blocked blood vessels and more can be treated
using minimally invasive techniques, preventing deadly or disabling
strokes, say U-M experts” (University
of Michigan Health System News Release, July 3, 2006). “One
of the newest options is the first device designed to help doctors open
up clogged blood vessels in the brain. Called the Wingspan
intracranial stent, it’s a tiny wire mesh tube that can be fed into the
body through an incision in the leg, threaded up through the blood
vessels in the chest and neck, and inserted into the brain.”
“It’s designed for patients with a condition called intracranial
stenosis, or cerebral atherosclerosis: a narrowing or hardening of the
arteries in the brain. The condition is linked to the same factors—high
cholesterol, high blood pressure, smoking, obesity, diabetes—that play
a role in many heart attacks. Just like in the heart, the
condition causes narrowing or blockage in brain blood vessels.”
“Another new
technology just became available for patients with AVMs, which occur in
more than 300,000 Americans and can also rupture suddenly and cause
permanent disability or death. This new treatment is a liquid
material called Onyx that can be injected directly into the AVM through
a tiny tube that is fed into the brain through the bloodstream. The
liquid quickly solidifies and cuts off the blood flow into the AVM,
reducing the risk of rupture. It can also be used in aneurysms.
After the procedure, the AVM can be more safely removed in open
surgery if needed.” (7/5/06)
195. Just Blade
Runners
Katrina Firlik,
a Connecticut neurosurgeon, is just out with
Another Day in the Frontal Lobe: A Brain Surgeon Exposes Life on the
Inside. “Good neurosurgeons (who, by the way, spend more
time operating on spines than they do on brains) like to keep things
simple” (“Maybe Brain Surgeons Aren’t as Smart as You Thought,” New
York Times, May 12, 2006, p. B33. Firlik’s book dwells
heavily on her life and career, but it also gives a pretty good tour of
the brain surgery world. The review of the book by William Grimes
in the Times is not terribly profound, and it more or less
suggests that brain surgery is no less, no more complicated than other
forms of surgical endeavor. It does make clear that Firlik is a
fairly vivid writer who can communicate about her world in terms the
layperson can surely understand. (6/28/06)
194. Neuro-Art
From “NeuroArt
Exhibition and Conference Honour Cajal and Golgi” (International Brain Research
Organization):
 
Left:
Molecular layer of the cerebellar cortex in a case of dementia
praecox (S.R. Cajal, 1926). Right: Central nervous system of the
Hirudo medicinalis (G. Retzius, 1891).
One hundred years ago
Santiago Ramón y Cajal and Camillo Golgi were jointly awarded
the Nobel Prize for Physiology or Medicine for their work on revealing
the structure of the brain. To honour this momentous occasion the
CosmoCaixa Science Museum, Barcelona, Spain is open its doors to the
NeuroArt Exhibition on 25 April 2006.
The exhibition is part of the
continuing effort by the CosmoCaixa, Barcelona Science Museum of La
Caixa Foundation, the International
Brain Research Organization and the Spanish Council for Scientific
Research (CSIC) to provide quality artistic and educational
resources related to Neurosciences. This will be a permanent
exhibition, but it will also tour other cities in Spain and around the
world.
The Exhibition
The exhibition contains three
sections:
The early period, commencing
with a detailed study of the nervous system, and containing contain
drawings of some of the most important pioneers in neuroscience,
including Cajal, Golgi, Retzius, Nissl, Dogiel and Alzheimer.
The untouched
nervous system, containing images such as those typically prepared for
a scientific article or that are commonly used as cover illustrations
in neuroscience journals.
  
Left: Hippocampus of a Brainbow mouse (J. Livet, J. R. Sanes, J.W.
Lichtman, 2006). Centre: Axonal rainbow (J. Livet, J. R. Sanes,
J.W. Lichtman, 2006). Right: Adult stem cells from human brain
(N. Sinai, A. Hinojosa, J.M. Garcia-Verdugo, A. Buylla, 2006).
The interpreted
nervous system, consisting of images modified by the authors in order
to express an idea or concept more clearly. (6/14/06)
193.
Mapping the Mind—in Detail
Julie H.
Simpson of the University of Wisconsin is doing a street map of
the mind—in this case a fruit fly’s mind—a project that probably will
go on the rest of her life. “With each slide, Simpson inches
closer to one of science’s more monumental goals: producing a
functional map as precise as a street map—first of the fly, eventually
of humans.” This will permit much more targeted treatments for
the sundry diseases and disorders of the mind. See Forbes,
November 14, 2005, pp. 89-90. There are a dozen or so labs
looking at neural circuitry of fruit flies, but Simpson is working a
wider canvas than most. Most are looking at a narrow brain
function: she has chosen to chart motor control which encompasses a lot
of behaviors. (6/7/06)
192. Nano-Hamsters
“Hamster Study
Shows Nanofibers Knit Severed Neurons Together, Restore Vision,” Scientific
American, March 14, 2006. Researchers at MIT, the University
of Hong Kong, and others cut a channel in the optic nerve of 53 newly
born hamsters. “The wounds of 10 of the pups were then treated
with 10 microliters of a solution composed of 99 percent water and 1
percent of a special ionic peptide. These short amino acids are
capable of creating a molecular scaffold that can bridge such
gaps.” Within 24 hours, the cuts began to close, and in 30 days
they were virtually healed. This was again tried with adult
hamsters, and significant vision returned to them. See
Scientific American. Also see the
Proceedings of the National Academy of Sciences. (5/31/06)
191. Teacher Education in Finland
The Finnish education system, whatever its
dilemmas, gets the very highest marks when compared with the offerings
of other nations in Europe and around the world. For this reason
it is stimulating to see what has been going on there in teacher
education. To this end, we recommend Hannele Niemi’s
“Teacher Education in Finland: Current Trends and Future Scenarios.”
There we learn that circa 1995 national law began to introduce more
flexibility into curriculum as well as teacher education. The
author notes that even insular Finland must, like every other country,
take account of a rapid changing |